This multi-center observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the licensed label will be followed for 6 months.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01670045?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
